Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.

To explore the predictive value of parameters derived from diffusion-weighted imaging (DWI) and contrast-enhanced (CE)-MRI at different time-points during neoadjuvant chemotherapy (NACT) in breast cancer. Institutional review board approval and written, informed consent from 42 breast cancer patients were obtained. The patients were investigated before and at three different time-points during neoadjuvant chemotherapy (NACT) using tumour diameter and volume from CE-MRI and ADC values obtained from drawn 2D and segmented 3D regions of interest. Prediction of pathologic complete response (pCR) was evaluated using the area under the curve (AUC) of receiver operating characteristic analysis.There was no significant difference between pathologic complete response and non-pCR in baseline size measures (p>0.39). Diameter change was significantly different in pCR (p<0.02) before the mid-therapy point. The best predictor was lesion diameter change observed before mid-therapy (AUC=0.93). Segmented volume was not able to differentiate between pCR and non-pCR at any time-point. The ADC values from 3D-ROI were not significantly different from 2D data (p=0.06). The best AUC (0.79) for pCR prediction using DWI was median ADC measured before mid-therapy of NACT.The results of this study should be considered in NACT monitoring planning, especially in MRI protocol designing and time point selection

Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.

To explore the predictive value of parameters derived from diffusion-weighted imaging (DWI) and contrast-enhanced (CE)-MRI at different time-points during neoadjuvant chemotherapy (NACT) in breast cancer. Institutional review board approval and written, informed consent from 42 breast cancer patients were obtained. The patients were investigated before and at three different time-points during neoadjuvant chemotherapy (NACT) using tumour diameter and volume from CE-MRI and ADC values obtained from drawn 2D and segmented 3D regions of interest. Prediction of pathologic complete response (pCR) was evaluated using the area under the curve (AUC) of receiver operating characteristic analysis.There was no significant difference between pathologic complete response and non-pCR in baseline size measures (p>0.39). Diameter change was significantly different in pCR (p<0.02) before the mid-therapy point. The best predictor was lesion diameter change observed before mid-therapy (AUC=0.93). Segmented volume was not able to differentiate between pCR and non-pCR at any time-point. The ADC values from 3D-ROI were not significantly different from 2D data (p=0.06). The best AUC (0.79) for pCR prediction using DWI was median ADC measured before mid-therapy of NACT.The results of this study should be considered in NACT monitoring planning, especially in MRI protocol designing and time point selection